Applying the Noninferiority Paradigm to Assess Exposure‐Response Similarity and Dose Between Pediatric and Adult Patients

The use of extrapolation of efficacy in pediatric drug development programs is possible when disease progression and treatment response are similar in adult and pediatric populations. Historically, the exposure‐response (E‐R) similarity was assessed by visual inspection of 2 E‐R curves to support pe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pharmacology 2021-06, Vol.61 (S1), p.S165-S174
Hauptverfasser: Zhang, Qunshu, Travis, James, Rothwell, Rebecca, Jay, Christopher E., Jahidur, Rashid, Zhang, Yifei, Crentsil, Victor, Altepeter, Tara, Lee, Jessica J., Burckart, Gilbert J., Ganley, Charles, Wang, Jian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The use of extrapolation of efficacy in pediatric drug development programs is possible when disease progression and treatment response are similar in adult and pediatric populations. Historically, the exposure‐response (E‐R) similarity was assessed by visual inspection of 2 E‐R curves to support pediatric extrapolation. The aim of this study was to develop a quantitative framework to describe the E‐R relationship and the difference in E‐R between pediatric and adult patients based on accumulated experience in pediatric drug development programs. Using clinical data for 8 drugs with either a linear or nonlinear E‐R relationship, we adapted the methodology used in noninferiority testing to assess the E‐R similarity between adult and pediatric patients at the targeted drug exposure. We implemented bootstrap‐based and Bayesian‐based methodologies to estimate the probability of concluding noninferiority of the E‐R relationship. This approach provides objective criteria that can be applied to an assessment of E‐R noninferiority in 2 populations to support extrapolation of efficacy in drug development programs from adults to pediatric populations.
ISSN:0091-2700
1552-4604
DOI:10.1002/jcph.1885